Quick Takeaways: Why It Matters? ECO Animal Health’s acceptance of field safety data for Ecovaxxin MS by the USDA‑CVB is a key regulatory step toward US licensure of its Mycoplasma synoviae poultry vaccine, following the product’s EU commercial launch in July 2026. The large fi...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
Quick Takeaways: Why It Matters? The $100M Symbiotic Capital facility, with $30M already drawn, gives TARGAN flexible, non‑dilutive growth capital, resets its lender base, and underwrites faster global deployment of WingScan at a time when revenues are already more th...
